Inhibrx Biosciences, Inc.
INBX•NASDAQ•Healthcare•Biotechnology

About Inhibrx Biosciences

Inhibrx Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of biologic therapeutics for people with life-threatening conditions. Its therapeutic candidates include INBRX-109, a tetravalent therapeutic candidate targeting death-receptor 5 to treat unresectable or metastatic conventional chondrosarcoma; and INBRX-106, a hexavalent sdAb-based therapeutic candidate targeting OX4 for the treatment of metastatic solid tumor, non-small cell lung cancer, melanoma, head and neck squamous cell carcinoma, gastric or gastroesophageal junction adenocarcinoma, renal cell carcinoma, and urothelial cell carcinoma. Inhibrx Biosciences, Inc. was incorporated in 2024 and is based in La Jolla, California.

Company Information

SectorHealthcare
IndustryBiotechnology
CEOMark Lappe
Founded2010
IPO DateAugust 19, 2020
Employees161
CountryUnited States
Fiscal YearJanuary - December

Stock Details

ExchangeNASDAQ (NASDAQ)
CurrencyUSD - USD
TypeStock
SubtypeCommon Stock

Contact Information

Websiteinhibrx.com
Phone858 795 4220
Address
11025 North Torrey Pines Road, Suite 140 La Jolla, California 92037 United States

Corporate Identifiers

CIK0001739614
CUSIP45720L107
ISINUS45720N1037
EIN82-4257312
SIC2836

Leadership Team & Key Executives

Mark Paul Lappe
Founder, Chief Executive Officer and Chairman
Kelly Devine Deck B.S., CPA, M.S.
Executive Vice President, Chief Financial Officer and Treasurer
David J. Matly M.B.A.
President
Bonne Adams M.B.A.
Vice President of Operations
Dr. Ashraf Amanullah Ph.D.
Executive Vice President and Chief Technical Operations Officer
Dr. Carlos Bais Ph.D.
Executive Vice President and Chief Scientific Officer
Leah Pollema J.D.
Vice President, General Counsel and Corporate Secretary
Dr. Josep Garcia Ph.D.
Executive Vice President and Chief Clinical Development Officer